Loading…
Cost‐effectiveness of screening for HLA‐B1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States
Objective Carbamazepine, widely used in the treatment of partial and generalized tonic–clonic seizures, has been associated with life‐threatening Stevens‐Johnson syndrome/toxic epidermal necrolysis among some Asians. The HLA‐B*1502 genotype that occurs with varying frequency among Asians is recommen...
Saved in:
| Published in: | Epilepsia (Copenhagen) 2019-07, Vol.60 (7), p.1472-1481 |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3533-1724a53bc898bdfed5d063a9088720f76ca62c28c340a34702506c96bf462a243 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3533-1724a53bc898bdfed5d063a9088720f76ca62c28c340a34702506c96bf462a243 |
| container_end_page | 1481 |
| container_issue | 7 |
| container_start_page | 1472 |
| container_title | Epilepsia (Copenhagen) |
| container_volume | 60 |
| creator | Choi, Hyunmi Mohit, Babak |
| description | Objective
Carbamazepine, widely used in the treatment of partial and generalized tonic–clonic seizures, has been associated with life‐threatening Stevens‐Johnson syndrome/toxic epidermal necrolysis among some Asians. The HLA‐B*1502 genotype that occurs with varying frequency among Asians is recommended for screening prior to starting carbamazepine. Our goal is to explore the cost‐effectiveness of screening for the presence of this genetic allele.
Methods
We constructed a Markov model in a hypothetical cohort of adult Asian patients with epilepsy in the United States being considered for carbamazepine to investigate the cost‐effectiveness of two alternative strategies: (1) no HLA‐B*1502 gene allele screening and using carbamazepine and (2) HLA‐B*1502 gene allele screening and starting levetiracetam in the case of a positive screen.
Results
For the lifetime horizon, HLA‐B*1502 gene screening was the cost‐effective choice compared to no gene screening, with an incremental cost‐effectiveness ratio of $27 058 per quality‐adjusted life‐year (QALY), below the $50 000/QALY threshold in 99.69% of probabilistic sensitivity analyses. Although gene screening strategy was more expensive than a no screening strategy, it was more effective, yielding more QALYs, across all Asian ethnic groups.
Significance
Our analysis confirms the 2007 US Food and Drug Administration recommendation to screen for HLA‐B*1502 allele before starting treatment with carbamazepine in patients of Asian ancestry in the United States. |
| doi_str_mv | 10.1111/epi.16053 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2252040024</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2252040024</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3533-1724a53bc898bdfed5d063a9088720f76ca62c28c340a34702506c96bf462a243</originalsourceid><addsrcrecordid>eNp1kMtOGzEUhq2qqITLgheoLLHqYuDYHnsmyxCFixSpSMB65PEcUyPiGWwHlK54BMQj9knqJJRdvbFlf_7OOT8hRwxOWF6nOLgTpkCKL2TEJK8LxlT1lYwAmCjGsoZdshfjAwBUqhLfyK5gTNYC1Ii8T_uY_ry-obVokntGjzHS3tJoAqJ3_p7aPtDL-SRDZ0wCp0Nw-Sb11HmXnE6u9-sPRodWL_Tv3IzH_Ebz4RGHuKJDZtCnjXYSnfZUe4MxhdUaS7-Q3mUTdvQm6YTxgOxY_Rjx8GPfJ3fns9vpZTH_eXE1ncwLI6QQBat4qaVoTT2u285iJztQQo-hrisOtlJGK254bUQJWpQVcAnKjFVrS8U1L8U-Od56h9A_LXM_zUO_DD6XbDiXHEqADfVjS5nQxxjQNnn-hQ6rhkGzTr_Jczab9DP7_cO4bBfYfZL_4s7A6RZ4ydGs_m9qZtdXW-VfkpGQUA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2252040024</pqid></control><display><type>article</type><title>Cost‐effectiveness of screening for HLA‐B1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Choi, Hyunmi ; Mohit, Babak</creator><creatorcontrib>Choi, Hyunmi ; Mohit, Babak</creatorcontrib><description>Objective
Carbamazepine, widely used in the treatment of partial and generalized tonic–clonic seizures, has been associated with life‐threatening Stevens‐Johnson syndrome/toxic epidermal necrolysis among some Asians. The HLA‐B*1502 genotype that occurs with varying frequency among Asians is recommended for screening prior to starting carbamazepine. Our goal is to explore the cost‐effectiveness of screening for the presence of this genetic allele.
Methods
We constructed a Markov model in a hypothetical cohort of adult Asian patients with epilepsy in the United States being considered for carbamazepine to investigate the cost‐effectiveness of two alternative strategies: (1) no HLA‐B*1502 gene allele screening and using carbamazepine and (2) HLA‐B*1502 gene allele screening and starting levetiracetam in the case of a positive screen.
Results
For the lifetime horizon, HLA‐B*1502 gene screening was the cost‐effective choice compared to no gene screening, with an incremental cost‐effectiveness ratio of $27 058 per quality‐adjusted life‐year (QALY), below the $50 000/QALY threshold in 99.69% of probabilistic sensitivity analyses. Although gene screening strategy was more expensive than a no screening strategy, it was more effective, yielding more QALYs, across all Asian ethnic groups.
Significance
Our analysis confirms the 2007 US Food and Drug Administration recommendation to screen for HLA‐B*1502 allele before starting treatment with carbamazepine in patients of Asian ancestry in the United States.</description><identifier>ISSN: 0013-9580</identifier><identifier>EISSN: 1528-1167</identifier><identifier>DOI: 10.1111/epi.16053</identifier><identifier>PMID: 31158306</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Alleles ; Anticonvulsants - adverse effects ; Anticonvulsants - economics ; Anticonvulsants - therapeutic use ; Asian Continental Ancestry Group - genetics ; Asian Continental Ancestry Group - statistics & numerical data ; Asian people ; Carbamazepine ; Carbamazepine - adverse effects ; Carbamazepine - economics ; Carbamazepine - therapeutic use ; cost ; Cost-Benefit Analysis ; cost‐effectiveness ; Epilepsy ; Epilepsy - drug therapy ; Epilepsy - economics ; Epilepsy - genetics ; Etiracetam ; Genetic Predisposition to Disease - genetics ; genetic screening ; Genetic Testing - economics ; Genotype ; Genotypes ; Health Care Costs ; Histocompatibility antigen HLA ; HLA-B15 Antigen - genetics ; HLA‐B1502 ; Humans ; Markov Chains ; Markov model ; Minority & ethnic groups ; pharmacovigilance ; public health ; QALY ; Quality-Adjusted Life Years ; Seizures ; Sensitivity analysis ; Skin diseases ; Stevens-Johnson Syndrome - economics ; Stevens-Johnson Syndrome - genetics ; Stevens‐Johnson syndrome ; Toxic epidermal necrolysis ; United States</subject><ispartof>Epilepsia (Copenhagen), 2019-07, Vol.60 (7), p.1472-1481</ispartof><rights>Wiley Periodicals, Inc. © 2019 International League Against Epilepsy</rights><rights>Wiley Periodicals, Inc. © 2019 International League Against Epilepsy.</rights><rights>Copyright © 2019 International League Against Epilepsy</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3533-1724a53bc898bdfed5d063a9088720f76ca62c28c340a34702506c96bf462a243</citedby><cites>FETCH-LOGICAL-c3533-1724a53bc898bdfed5d063a9088720f76ca62c28c340a34702506c96bf462a243</cites><orcidid>0000-0002-6059-6681</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31158306$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Choi, Hyunmi</creatorcontrib><creatorcontrib>Mohit, Babak</creatorcontrib><title>Cost‐effectiveness of screening for HLA‐B1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States</title><title>Epilepsia (Copenhagen)</title><addtitle>Epilepsia</addtitle><description>Objective
Carbamazepine, widely used in the treatment of partial and generalized tonic–clonic seizures, has been associated with life‐threatening Stevens‐Johnson syndrome/toxic epidermal necrolysis among some Asians. The HLA‐B*1502 genotype that occurs with varying frequency among Asians is recommended for screening prior to starting carbamazepine. Our goal is to explore the cost‐effectiveness of screening for the presence of this genetic allele.
Methods
We constructed a Markov model in a hypothetical cohort of adult Asian patients with epilepsy in the United States being considered for carbamazepine to investigate the cost‐effectiveness of two alternative strategies: (1) no HLA‐B*1502 gene allele screening and using carbamazepine and (2) HLA‐B*1502 gene allele screening and starting levetiracetam in the case of a positive screen.
Results
For the lifetime horizon, HLA‐B*1502 gene screening was the cost‐effective choice compared to no gene screening, with an incremental cost‐effectiveness ratio of $27 058 per quality‐adjusted life‐year (QALY), below the $50 000/QALY threshold in 99.69% of probabilistic sensitivity analyses. Although gene screening strategy was more expensive than a no screening strategy, it was more effective, yielding more QALYs, across all Asian ethnic groups.
Significance
Our analysis confirms the 2007 US Food and Drug Administration recommendation to screen for HLA‐B*1502 allele before starting treatment with carbamazepine in patients of Asian ancestry in the United States.</description><subject>Adult</subject><subject>Alleles</subject><subject>Anticonvulsants - adverse effects</subject><subject>Anticonvulsants - economics</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Asian Continental Ancestry Group - genetics</subject><subject>Asian Continental Ancestry Group - statistics & numerical data</subject><subject>Asian people</subject><subject>Carbamazepine</subject><subject>Carbamazepine - adverse effects</subject><subject>Carbamazepine - economics</subject><subject>Carbamazepine - therapeutic use</subject><subject>cost</subject><subject>Cost-Benefit Analysis</subject><subject>cost‐effectiveness</subject><subject>Epilepsy</subject><subject>Epilepsy - drug therapy</subject><subject>Epilepsy - economics</subject><subject>Epilepsy - genetics</subject><subject>Etiracetam</subject><subject>Genetic Predisposition to Disease - genetics</subject><subject>genetic screening</subject><subject>Genetic Testing - economics</subject><subject>Genotype</subject><subject>Genotypes</subject><subject>Health Care Costs</subject><subject>Histocompatibility antigen HLA</subject><subject>HLA-B15 Antigen - genetics</subject><subject>HLA‐B1502</subject><subject>Humans</subject><subject>Markov Chains</subject><subject>Markov model</subject><subject>Minority & ethnic groups</subject><subject>pharmacovigilance</subject><subject>public health</subject><subject>QALY</subject><subject>Quality-Adjusted Life Years</subject><subject>Seizures</subject><subject>Sensitivity analysis</subject><subject>Skin diseases</subject><subject>Stevens-Johnson Syndrome - economics</subject><subject>Stevens-Johnson Syndrome - genetics</subject><subject>Stevens‐Johnson syndrome</subject><subject>Toxic epidermal necrolysis</subject><subject>United States</subject><issn>0013-9580</issn><issn>1528-1167</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kMtOGzEUhq2qqITLgheoLLHqYuDYHnsmyxCFixSpSMB65PEcUyPiGWwHlK54BMQj9knqJJRdvbFlf_7OOT8hRwxOWF6nOLgTpkCKL2TEJK8LxlT1lYwAmCjGsoZdshfjAwBUqhLfyK5gTNYC1Ii8T_uY_ry-obVokntGjzHS3tJoAqJ3_p7aPtDL-SRDZ0wCp0Nw-Sb11HmXnE6u9-sPRodWL_Tv3IzH_Ebz4RGHuKJDZtCnjXYSnfZUe4MxhdUaS7-Q3mUTdvQm6YTxgOxY_Rjx8GPfJ3fns9vpZTH_eXE1ncwLI6QQBat4qaVoTT2u285iJztQQo-hrisOtlJGK254bUQJWpQVcAnKjFVrS8U1L8U-Od56h9A_LXM_zUO_DD6XbDiXHEqADfVjS5nQxxjQNnn-hQ6rhkGzTr_Jczab9DP7_cO4bBfYfZL_4s7A6RZ4ydGs_m9qZtdXW-VfkpGQUA</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Choi, Hyunmi</creator><creator>Mohit, Babak</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><orcidid>https://orcid.org/0000-0002-6059-6681</orcidid></search><sort><creationdate>201907</creationdate><title>Cost‐effectiveness of screening for HLA‐B1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States</title><author>Choi, Hyunmi ; Mohit, Babak</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3533-1724a53bc898bdfed5d063a9088720f76ca62c28c340a34702506c96bf462a243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Alleles</topic><topic>Anticonvulsants - adverse effects</topic><topic>Anticonvulsants - economics</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Asian Continental Ancestry Group - genetics</topic><topic>Asian Continental Ancestry Group - statistics & numerical data</topic><topic>Asian people</topic><topic>Carbamazepine</topic><topic>Carbamazepine - adverse effects</topic><topic>Carbamazepine - economics</topic><topic>Carbamazepine - therapeutic use</topic><topic>cost</topic><topic>Cost-Benefit Analysis</topic><topic>cost‐effectiveness</topic><topic>Epilepsy</topic><topic>Epilepsy - drug therapy</topic><topic>Epilepsy - economics</topic><topic>Epilepsy - genetics</topic><topic>Etiracetam</topic><topic>Genetic Predisposition to Disease - genetics</topic><topic>genetic screening</topic><topic>Genetic Testing - economics</topic><topic>Genotype</topic><topic>Genotypes</topic><topic>Health Care Costs</topic><topic>Histocompatibility antigen HLA</topic><topic>HLA-B15 Antigen - genetics</topic><topic>HLA‐B1502</topic><topic>Humans</topic><topic>Markov Chains</topic><topic>Markov model</topic><topic>Minority & ethnic groups</topic><topic>pharmacovigilance</topic><topic>public health</topic><topic>QALY</topic><topic>Quality-Adjusted Life Years</topic><topic>Seizures</topic><topic>Sensitivity analysis</topic><topic>Skin diseases</topic><topic>Stevens-Johnson Syndrome - economics</topic><topic>Stevens-Johnson Syndrome - genetics</topic><topic>Stevens‐Johnson syndrome</topic><topic>Toxic epidermal necrolysis</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choi, Hyunmi</creatorcontrib><creatorcontrib>Mohit, Babak</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Epilepsia (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choi, Hyunmi</au><au>Mohit, Babak</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost‐effectiveness of screening for HLA‐B1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States</atitle><jtitle>Epilepsia (Copenhagen)</jtitle><addtitle>Epilepsia</addtitle><date>2019-07</date><risdate>2019</risdate><volume>60</volume><issue>7</issue><spage>1472</spage><epage>1481</epage><pages>1472-1481</pages><issn>0013-9580</issn><eissn>1528-1167</eissn><abstract>Objective
Carbamazepine, widely used in the treatment of partial and generalized tonic–clonic seizures, has been associated with life‐threatening Stevens‐Johnson syndrome/toxic epidermal necrolysis among some Asians. The HLA‐B*1502 genotype that occurs with varying frequency among Asians is recommended for screening prior to starting carbamazepine. Our goal is to explore the cost‐effectiveness of screening for the presence of this genetic allele.
Methods
We constructed a Markov model in a hypothetical cohort of adult Asian patients with epilepsy in the United States being considered for carbamazepine to investigate the cost‐effectiveness of two alternative strategies: (1) no HLA‐B*1502 gene allele screening and using carbamazepine and (2) HLA‐B*1502 gene allele screening and starting levetiracetam in the case of a positive screen.
Results
For the lifetime horizon, HLA‐B*1502 gene screening was the cost‐effective choice compared to no gene screening, with an incremental cost‐effectiveness ratio of $27 058 per quality‐adjusted life‐year (QALY), below the $50 000/QALY threshold in 99.69% of probabilistic sensitivity analyses. Although gene screening strategy was more expensive than a no screening strategy, it was more effective, yielding more QALYs, across all Asian ethnic groups.
Significance
Our analysis confirms the 2007 US Food and Drug Administration recommendation to screen for HLA‐B*1502 allele before starting treatment with carbamazepine in patients of Asian ancestry in the United States.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31158306</pmid><doi>10.1111/epi.16053</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-6059-6681</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0013-9580 |
| ispartof | Epilepsia (Copenhagen), 2019-07, Vol.60 (7), p.1472-1481 |
| issn | 0013-9580 1528-1167 |
| language | eng |
| recordid | cdi_proquest_journals_2252040024 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adult Alleles Anticonvulsants - adverse effects Anticonvulsants - economics Anticonvulsants - therapeutic use Asian Continental Ancestry Group - genetics Asian Continental Ancestry Group - statistics & numerical data Asian people Carbamazepine Carbamazepine - adverse effects Carbamazepine - economics Carbamazepine - therapeutic use cost Cost-Benefit Analysis cost‐effectiveness Epilepsy Epilepsy - drug therapy Epilepsy - economics Epilepsy - genetics Etiracetam Genetic Predisposition to Disease - genetics genetic screening Genetic Testing - economics Genotype Genotypes Health Care Costs Histocompatibility antigen HLA HLA-B15 Antigen - genetics HLA‐B1502 Humans Markov Chains Markov model Minority & ethnic groups pharmacovigilance public health QALY Quality-Adjusted Life Years Seizures Sensitivity analysis Skin diseases Stevens-Johnson Syndrome - economics Stevens-Johnson Syndrome - genetics Stevens‐Johnson syndrome Toxic epidermal necrolysis United States |
| title | Cost‐effectiveness of screening for HLA‐B1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T11%3A45%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%E2%80%90effectiveness%20of%20screening%20for%20HLA%E2%80%90B1502%20prior%20to%20initiation%20of%20carbamazepine%20in%20epilepsy%20patients%20of%20Asian%20ancestry%20in%20the%20United%20States&rft.jtitle=Epilepsia%20(Copenhagen)&rft.au=Choi,%20Hyunmi&rft.date=2019-07&rft.volume=60&rft.issue=7&rft.spage=1472&rft.epage=1481&rft.pages=1472-1481&rft.issn=0013-9580&rft.eissn=1528-1167&rft_id=info:doi/10.1111/epi.16053&rft_dat=%3Cproquest_cross%3E2252040024%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3533-1724a53bc898bdfed5d063a9088720f76ca62c28c340a34702506c96bf462a243%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2252040024&rft_id=info:pmid/31158306&rfr_iscdi=true |